Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?

• DOI: 10.1007/s00125-024-06100-z
• Publication Date: 2024-02-20T13:02:53Z
• Authors: Sophie Béliard; Florian Mourre; René Valéro
• Keywords: PCSK9; Prediabetes; Ezetimibe; Dyslipidemia

Abstract Dyslipidaemias are major cardiovascular risk factors, especially in people with diabetes. In this area, next-generation therapies targeting circulating lipoparticle metabolism (LDL, VLDL, chylomicrons, HDL) have recently been approved by the European and US medical agencies, including anti- proprotein convertase subtilisin/kexin 9 (PCSK9) antibodies; an siRNA PCSK9; bempedoic acid, which targets ATP citrate lyase; antisense oligonucleotide apolipoprotein C-III; anti-angiopoietin-like 3 antibody; a purified omega-3 fatty icosapent ethyl. Other different phases of development. There several important considerations concerning link between these new lipid-lowering First, since concerns were first raised 2008 about increased new-onset diabetes mellitus (NODM) intensive statin treatment, each therapy is being evaluated for its associated NODM, particularly individuals prediabetes (impaired fasting glucose and/or impaired tolerance). Second, represent large proportion those at high or very whom drugs currently, will be, prescribed. Thus, efficacy subgroups should also be closely considered, as well any potential effects on glycaemic control. review, we describe lipoprotein their control normoglycaemic individuals. Graphical